Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat in Uncontrolled and Resistant Hypertension
NCT06034743Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of baxdrostat in hypertension (HTN), resistant hypertension (RH), sponsored by AstraZeneca. Started Nov 2023; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on NCT06034743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034743.